Syntach, a Lund, Sweden-based medtech startup, raised €17.5M in Equity financing.
This included:
- an up to €15M in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a device for patients with heart failure,
- a €2.5M grant from the EIC announced in December 2021.
The company intends to use the funds to develop the Syntach Cardiac Support System, a device for patients with heart failure.
Led by new CEO Patrick N.J. Schnegelsberg, Syntach develops innovative cardiac support systems as well as mitral valve intervention systems in cooperation with several academic research centers. The company works with the Cardiac MR Group at the Department for Clinical Sciences and Clinical Physiology at Lund University.
Patrick NJ Schnegelsberg brings over two decades of industry experience and expertise to Syntach. Most recently, he served as Chief Operating Officer with the Occlutech Group. Schnegelsberg also held C-level positions at medtech and biotech start-ups as well as Director positions with buy- and sell-side firms on Wall Street. He also serves on the boards of Acorai and Scandinavian Real Heart.
FinSMEs
31/01/2023